Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
- Conditions
- Heart Failure
- Registration Number
- NCT04983823
- Lead Sponsor
- Baker Heart and Diabetes Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 820
Inclusion Criteria:<br><br> 1. History of COVID-19 infection<br><br> 2. Live within a geographically accessible area for follow-up<br><br>Exclusion Criteria:<br><br> 1. Valvular stenosis or regurgitation of >moderate severity<br><br> 2. History of previous heart failure (baseline New York Heart Association (NYHA)<br> classification >2)<br><br> 3. Inability to acquire interpretable images (identified from baseline echo)<br><br> 4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors<br><br> 5. Oncologic (or other) life expectancy <12 months or any other medical condition<br> (including pregnancy) that results in the belief (deemed by the Chief Investigators)<br> that it is not appropriate for the patient to participate in this trial<br><br> 6. Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor<br> blockers and beta blockers, or intolerance (or allergy) to both.<br><br> 7. Mobility impairment that would impact participants' ability to perform exercise<br><br> 8. Unable to provide written informed consent to participate in this study
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in exercise capacity
- Secondary Outcome Measures
Name Time Method New onset heart failure;Change in maximal isometric grip strength;Change on quality of life